Combining diagnostic tests that include imaging and cerebrospinal fluid biomarkers can improve prediction of a patient progressing from mild cognitive impairment to Alzheimer’s disease, according to a study published Dec. 11 in Radiology.
Duke Medicine researchers reviewed three tests — magnetic resonance imaging (MRI), fluorine 18 fluorodeoxyglucose positron emission tomography (FDG-PET), and cerebrospinal fluid analysis — to learn whether the trio were more accurate than single tests. The study subjects also were given routine clinical exams.
From the January 01, 2013 Issue of McKnight's Long-Term Care News
